Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg, Packaged as (a) 30-count bottle, NDC 6...

FDA Drug Recall #D-0112-2024 — Class III — October 23, 2023

Recall Summary

Recall Number D-0112-2024
Classification Class III — Low risk
Date Initiated October 23, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Glenmark Pharmaceuticals Inc., USA
Location Mahwah, NJ
Product Type Drugs
Quantity 8,448 30-count bottles, 168 1000-count bottles

Product Description

Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg, Packaged as (a) 30-count bottle, NDC 68462-390-30; (b) 1000-count Bottle, NDC 68462-390-10: RX Only, Manufactured for: Glenmark, Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India,

Reason for Recall

Failed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in long term stability study (25¿C/60% RH).

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot # 17220002, Exp Date 11/30/2023

Other Recalls from Glenmark Pharmaceuticals Inc., USA

Recall # Classification Product Date
D-0246-2026 Class II Ondansetron Orally Disintegrating Tablets, USP,... Dec 30, 2025
D-0199-2026 Class III Bisoprolol Fumarate and Hydrochlorothiazide Tab... Nov 21, 2025
D-0222-2026 Class III Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... Nov 18, 2025
D-0662-2025 Class II Azelaic Acid Gel, 15%, 50 grams, For Topical Us... Sep 17, 2025
D-0021-2026 Class II Viorele, Desogestrel and Ethinyl Estradiol, USP... Sep 3, 2025

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.